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The marked improvement in survival and reduced mor-
bidity in thalassemia major (TM) allows many patients
to parent children (1, 2). For women, in many
instances assisted reproduction methods in vitro fertil-
ization (IVF) need to be used. In general, as pregnan-
cies in TM patients are usually planned, iron chelation
therapy is stopped before the patient enters the IVF
programme (3). In the past, the impact of such cessa-
tion was not easily assessable except by serum ferritin
levels. Liver biopsies, though valuable were relatively
traumatic and had low acceptance from patients. With
the advent of magnetic resonance imaging (MRI) tech-
niques such assessments are more easily accessible (4).
The patient, subject of this report was followed pro-
spectively before and after a pregnancy to determine
the impact of withholding chelation therapy for a per-
iod of 12 months.
Patient information
The patient is now 38 yr old. She commenced regular
blood transfusion at 10 months of age and desferriox-
amine iron chelation therapy at the age of 11 yr. In June
2001 with the availability of the oral chelator deferi-
prone, she commenced combination therapy with deferi-
prone at 60–80 mg⁄kg⁄d in three doses (25% in the
morning, 25% in the afternoon and 50% at night) and
desferrioxamine at 30–50 mg⁄kg⁄infusion⁄d. She was
always very compliant with her chelation therapy. She
Abstract
In general, in women with transfusion-dependent thalassemia, during pregnancy, iron chelation therapy is
ceased. We report a splenectomized patient, who was an excellent complier with chelation therapy, who
before embarking on a pregnancy showed no evidence of iron overload, with normal cardiac, thyroid func-
tion and glucose metabolism. Laboratory ﬁndings showed ferritin 67 lg⁄L, myocardial T2* of 34 ms and
liver magnetic resonance imaging (MRI) liver iron concentration of 1 mg⁄g dry weight. She became preg-
nant by in vitro fertilization in October 2006, delivery occurred in June 2007. She breast fed for 2 months.
After 12 months without iron chelation, ferritin was 1583 lg⁄L. Quantitative MRI showed myocardial T2*
of 27 ms, that the liver iron concentration had increased to 11.3 mg⁄g dry weight, indicative of moderate
to heavy iron load. This case demonstrates that iron overload can develop rapidly and that physicians car-
ing for patients with transfusion-dependent thalassemia should be particularly alert to any discontinuation
of chelation therapy over time.
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thyroid metabolism were normal. She was diagnosed as
having primary amenorrhea at 16 yr of age and received
hormone replacement therapy. She had osteopenia. In
October 2006 with IVF she became pregnant. She deliv-
ered in June 2007 and breast fed for 2 months. She had
ceased chelation therapy from October 2006 till the end
of September 2007. She has given written consent to the
anonymous publication of this report.
Liver R2* (reciprocal of T2*) is linearly proportional
to total iron present in an organ and a calibration equa-
tion was derived from the least squares ﬁt of liver R2*
data of patients who subsequently underwent liver biopsy
vs. linear ion concentration (LIC) determined by the liver
biopsies. For liver R2 vs. LIC a non-linear calibration
curve was determined and a calibration equation is also
available (5). In order to use the calibration equations
for liver R2* and R2 the same protocols for determining
R2 and R2* must of course be used. Our R2* data were
obtained with identical protocols as described from a
Los Angeles group (6) but a different pulse sequence was
used for determining R2, thus our R2 data can only be
correlated to LIC in a qualitative way. For the period of
the pregnancy all quantitative determinations are based
on our R2* data.
Table 1 shows the mean ferritin levels, the red cell con-
sumption, left ventricular ejection fraction (LVEF) as
assessed by echocardiography, cardiac T2* and liver iron
concentration. The initial and ﬁnal LIC were determined
from the MRI data were estimated to be 1.0 and
11.3 mg⁄g dry weight, respectively, indicative of normal
and moderate to heavy iron load, respectively. The MRI-
derived LVEF at the end of the pregnancy was 63%,
indicating marginal normal function.
The most striking feature of her results was the rise
in the mean ferritin from 46 lg⁄L, just before the preg-
nancy to 1583 lg⁄L after delivery. Liver R2* rose from
1.3 mg⁄g dry weight to 11.3 mg⁄g dry weight and car-
diac T2* fell mildly from 34.1 to 27.3 ms (albeit still
within the normal range but with a downward trend).
Even though her LVEF as assessed by MRI remained
normal, it is at the lower limit of normal. She was
transfused 33 times during the 9 months receiving a
total of 11 417 mL of packed red blood cells. The
packed red blood cells given, apart from the anticoagu-
lant solution, are enriched with 100 mL of mannitol
additive solution after plasma separation in order to
prolong red blood cells conservation to 42 d instead of
35 d. Each unit is about 300–350 mL instead of 200–
250 mL. The mannitol additive solution (3300 mL for
the 33 units) containing only glucose is not regarded as
an iron source. The 11 417 mL of packed cells given
are equivalent to 8117 mL of conventional red blood
cells and would translate to 6.5 g of iron input. Even
though the mean pretransfusion Hb level was main-
tained at 10.8 g⁄dL her red cell consumption remained
unchanged because she had gained 10 kg weight. The
total amount of iron received during the pregnancy was
higher than usual owing to her weight gain. The liver
iron concentration before combination therapy had
shown a R2 value >50⁄s (indicative of moderate to
heavy hepatic iron loading) and by 2006 it had
improved to 29.4⁄s.
The liver during the 12-month chelation-free period
accumulated 10.3 mg⁄g dry weight, i.e. 0.85 mg⁄g dry
weight per month. This is equivalent to an increased
total body iron load of 109 mg⁄kg and is compatible
with the 6.5 g of iron she received through transfusion
during the period without chelation therapy.
Discussion
This case report demonstrates the iron loading that
occurred in one individual patient after the usual practice
of cessation of iron chelation therapy for pregnancy. It
would be valuable to have results from more patients. It
would also seem that the policy of ceasing chelation ther-
apy during the whole of pregnancy may be inadvisable
and may be placing patients at risk of increased morbid-
ity and ultimately mortality, especially during a period in
which their cardiac function may need to be at its best.
In the experience of one of the authors (VB), armed with
the understanding that desferrioxamine is not terato-
genic, recommencing regular chelation therapy with
desferrioxamine after the 16th week of gestation did not
result in any fetal abnormalities. In addition, a number
of patients who became pregnant unexpectedly and did
not stop desferrioxamine therapy until they were aware
of the pregnancy had normal outcomes to their off-
spring. A case report of a patient who received desferri-
oxamine chelation therapy and gave birth to a normal
Table 1 Iron load parameters over time
Year
Annual
mean
ferritin RCC LVEF
T2
heart
T2*
heart
LIC
mg⁄gd w
2001 1500 230 77% 35.5
2002 126 251 66% 39.6
2003 92 210 69% 32.8 35.4 1
2004 105 229 67% 38.0 35.3 1.3
2005 142 257 61% 37.8 34.4 1.2
2006 67 242 63% 38.3 34.1 1
2007 1481 230 65% 33.8 27.3 11.3
RCC is the red cell consumption per annum in mL⁄kg.
LIC is expressed as mg⁄g dry weight and was assessed by magnetic
resonance imaging T2 and T2*.
All T values are in milliseconds.
LVEF, left ventricular ejection fraction; LIC, liver iron concentration.
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pregnancy (7).
It is also likely that the free iron that results from the
iron overload may be very avidly taken up in the liver
and possibly the heart (8).
Conclusion
This case report shows clearly that pregnant women with
TM should be monitored carefully for iron loading
before they embark upon a pregnancy and afterwards
and consideration should be given to offering desferriox-
amine chelation therapy after the middle of the second
trimester. The main message from this patient is that in
some transfusion-dependent patients, cessation of chela-
tion therapy allows rapid iron overload. Patients should
be made aware of this risk in order to encourage them to
maintain their chelation therapy consistently.
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